Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Biomarkers for frontotemporal dementia

Julio Rojas-Martinez, MD, PhD, University of California San Francisco, San Francisco, CA, talks on the development of biomarkers for frontotemporal dementia (FTD), including a comparison of imaging biomarkers and blood biomarkers. A blood test is often cheaper and quicker than sending a patient for imaging scans, so the identification of accurate and reliable blood tests and biomarkers could be a useful clinical tool for dementia care. Dr Rojas-Martinez explains the development of more sensitive techniques to test for small molecules in blood in recent decades and highlights the collaborative work between large medical centers in the US and Europe, which has led to a greater understanding of biomarkers of FTD as well as the underlying biological mechanisms of disease. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.


Dr Rojas-Martinez reports the following disclosures:
Site PI for clinical trials sponsored by Eli Lilly and Eisai.